As ASCO 2026 made clear, oncology has entered a “post-molecule” era, where clinical efficacy is no longer the primary differentiator, but a baseline expectation.
In a new article for PharmaLive, Tim Lewis explores how success now depends on how well therapies integrate into an increasingly complex, overburdened care ecosystem.
Key shifts emerging from ASCO include:
- Greater emphasis on applying diagnostic insights (e.g., ctDNA) to guide treatment decisions
- A growing need to reduce “administrative toxicity” by embedding solutions into clinical workflows
- Recognition that discovery alone isn’t enough – translation into real-world care is what drives impact
For marketers, this means moving beyond product-centric strategies to designing solutions that support the full care journey.
From Pre-ASCO Signals to Post-ASCO Reality
Prior to ASCO, EVERSANA published a series of white papers exploring the forces reshaping oncology commercialization:
- The Shattered Glass — calling for a shift from fragmented portals to embedded, agent-driven patient support ecosystems
- Decoding the Dialogue — highlighting how AI can transform MSL interactions into actionable insight
- The Indispensable Edge — underscoring the need for an AI-powered, agentic approach to modern marketing
Together, these papers anticipated a move toward more connected, intelligent, and workflow-embedded models of commercialization.
This new thought leadership article represents the culmination of these ideas following ASCO, grounding them in real-world observations from the congress and highlighting how this shift is already taking shape across diagnostics, care delivery, and clinical workflows.
The Takeaway
Oncology commercialization is no longer about the molecule alone. The brands that will lead are those that can orchestrate data, workflows, and support into a seamless ecosystem around the patient and provider.
Read the full article in Med Ad News/Pharmalive.com